CJC-1295 / Ipamorelin blend
Common combination vial pairing a GHRH analogue with a GH secretagogue. Sold premixed.
Peptides
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
CJC-1295 / Ipamorelin blend
Common combination vial pairing a GHRH analogue with a GH secretagogue. Sold premixed.
Evidence category: Clinical study. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
Human data covers the separate parts, not the blends sold today. A randomised placebo-controlled trial of CJC-1295 in healthy adults found dose-dependent rises in growth hormone and IGF-1, with no serious adverse reactions reported, and a second study found growth hormone pulses were preserved. Ipamorelin's own evidence is preclinical. Neither compound is approved for any use, and a 2026 review of peptide use in sport warns that supply is largely unregulated, with mislabelled or contaminated products and risks including cardiovascular strain and insulin resistance.
Benefits reported in the imported source
- A placebo-controlled trial of CJC-1295 raised growth hormone and IGF-1 in healthy adults
- No serious adverse reactions were reported in that trial, and growth hormone pulses persisted
Risks and limits
- Human data covers the separate parts, not the blends sold today; ipamorelin's data is preclinical
- Neither compound is approved for any use
- A review warns supply is unregulated, with mislabelled or contaminated products and heart strain
Source bottom line: Human data exists for CJC-1295 alone, not the blend; neither part is approved and supply is unregulated.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
healthy adults aged 21-61 in two randomised, placebo-controlled, double-blind ascending-dose trials
- Reported regimen
- CJC-1295 subcutaneously, as single ascending doses in one trial and as two or three weekly or biweekly doses in the other
- Duration
- 28 days and 49 days
- Reported outcome
- Mean plasma GH rose 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days; no serious adverse reactions were reported.
- Source
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman et al. 2006)
Claim provenance
evidence.json#/catalog:peptide:cjc-ipamorelin-blend/protocols/0
healthy men aged 20-40 years
- Reported regimen
- a single injection of 60 or 90 micrograms per kg of CJC-1295, with 20-minute blood sampling over 12 h before and 1 week after
- Duration
- single dose
- Reported outcome
- Trough GH rose 7.5-fold, mean GH 46% and IGF-1 45%, with pulse frequency and magnitude unchanged; the two doses did not differ.
- Source
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (Ionescu 2006)
Claim provenance
evidence.json#/catalog:peptide:cjc-ipamorelin-blend/protocols/1
rat pituitary cells, pentobarbital-anaesthetised rats and conscious swine
- Reported regimen
- single doses of ipamorelin; ED50 80 nmol/kg in rats and 2.3 nmol/kg in swine
- Duration
- single dose
- Reported outcome
- Ipamorelin released GH with potency and efficacy similar to GHRP-6 and, unlike GHRP-6 and GHRP-2, did not raise ACTH or cortisol.
- Source
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al. 1998)
Claim provenance
evidence.json#/catalog:peptide:cjc-ipamorelin-blend/protocols/2
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — CJC-1295/Ipamorelin Dosage Protocol: The Complete Clinical Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: formulation context limited. The attached trials concern individual components, not a clinical trial of this premixed blend. A community account about CJC-1295 with DAC does not establish a regimen for a CJC/ipamorelin blend or for no-DAC CJC. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A protocol documented on fitness forums describes starting CJC-1295/ipamorelin blend at 0.3 mg daily before bedtime, escalating by 0.1 mg weekly for 8 weeks until reaching 1.0 mg daily maintenance, administered 5 days per week with 2 rest days.
CJC-1295/Ipamorelin Dosage Protocol: The Complete Clinical Guide
Unverified imported account — CJC-1295 & Sermorelin: Complete Dosing, Administration & Safety Guide
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: formulation context limited. The attached trials concern individual components, not a clinical trial of this premixed blend. A community account about CJC-1295 with DAC does not establish a regimen for a CJC/ipamorelin blend or for no-DAC CJC. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: CJC-1295 (with DAC) athletic recovery protocols described in dosing guides suggest 1-2 mg administered once or twice per week in the evening.
CJC-1295 & Sermorelin: Complete Dosing, Administration & Safety Guide
Pharmacokinetic context
No half-life recorded in this source snapshot. No value has been inferred.
Source references
- Peptide Wiki: CJC-1295 / Ipamorelin blend (wiki-origin reference; not independent corroboration)
- Peptide Wiki: CJC-1295 / Ipamorelin blend (wiki-origin reference; not independent corroboration)
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (Teichman et al. 2006)
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog (Ionescu 2006)
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (Coutinho et al. 2026)
- Ipamorelin, the first selective growth hormone secretagogue (Raun et al. 1998)
- PubMed: growth hormone secretagogues (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
Snapshot provenance
Source ID: catalog:peptide:cjc-ipamorelin-blend. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.